JP2015527296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527296A5 JP2015527296A5 JP2015503322A JP2015503322A JP2015527296A5 JP 2015527296 A5 JP2015527296 A5 JP 2015527296A5 JP 2015503322 A JP2015503322 A JP 2015503322A JP 2015503322 A JP2015503322 A JP 2015503322A JP 2015527296 A5 JP2015527296 A5 JP 2015527296A5
- Authority
- JP
- Japan
- Prior art keywords
- vlp
- polynucleotide
- virus
- protein
- sequence encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000710929 Alphavirus Species 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 241000710960 Sindbis virus Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 241000710961 Semliki Forest virus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims 16
- 102000040430 polynucleotide Human genes 0.000 claims 16
- 239000002157 polynucleotide Substances 0.000 claims 16
- 210000003527 eukaryotic cell Anatomy 0.000 claims 6
- 101710091045 Envelope protein Proteins 0.000 claims 4
- 101710177291 Gag polyprotein Proteins 0.000 claims 4
- 101710125418 Major capsid protein Proteins 0.000 claims 4
- 101710188315 Protein X Proteins 0.000 claims 4
- 102100021696 Syncytin-1 Human genes 0.000 claims 4
- 239000013612 plasmid Substances 0.000 claims 4
- 101710172711 Structural protein Proteins 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 230000001177 retroviral effect Effects 0.000 claims 3
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 241000714474 Rous sarcoma virus Species 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 102100028253 Breast cancer anti-estrogen resistance protein 3 Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 1
- 101710154606 Hemagglutinin Proteins 0.000 claims 1
- 101710145006 Lysis protein Proteins 0.000 claims 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 claims 1
- 241000714177 Murine leukemia virus Species 0.000 claims 1
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 claims 1
- 101710144127 Non-structural protein 1 Proteins 0.000 claims 1
- 101710144128 Non-structural protein 2 Proteins 0.000 claims 1
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 1
- 101710176177 Protein A56 Proteins 0.000 claims 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims 1
- 102100031776 SH2 domain-containing protein 3A Human genes 0.000 claims 1
- 102100021798 SH2 domain-containing protein 3C Human genes 0.000 claims 1
- 102100031056 Serine protease 57 Human genes 0.000 claims 1
- 101710197596 Serine protease 57 Proteins 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000120 cytopathologic effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000000185 hemagglutinin Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000710912 Kunjin virus Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615687P | 2012-03-26 | 2012-03-26 | |
| US61/615,687 | 2012-03-26 | ||
| PCT/US2013/031876 WO2013148302A1 (en) | 2012-03-26 | 2013-03-15 | Delivery of packaged rna to mammalian cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018111489A Division JP6585237B2 (ja) | 2012-03-26 | 2018-06-12 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015527296A JP2015527296A (ja) | 2015-09-17 |
| JP2015527296A5 true JP2015527296A5 (enExample) | 2016-05-12 |
Family
ID=47998556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503322A Pending JP2015527296A (ja) | 2012-03-26 | 2013-03-15 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
| JP2018111489A Active JP6585237B2 (ja) | 2012-03-26 | 2018-06-12 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018111489A Active JP6585237B2 (ja) | 2012-03-26 | 2018-06-12 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9506041B2 (enExample) |
| EP (2) | EP3663395B1 (enExample) |
| JP (2) | JP2015527296A (enExample) |
| AU (3) | AU2013240248B2 (enExample) |
| WO (1) | WO2013148302A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| EP3663395B1 (en) | 2012-03-26 | 2024-07-31 | The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology, Transfer, | Delivery of packaged rna to mammalian cells |
| KR102467982B1 (ko) * | 2013-12-16 | 2022-11-16 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법 |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| WO2016037164A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
| FR3036118B1 (fr) * | 2015-05-15 | 2019-07-12 | Flash Therapeutics | Particule retrovirale comportant au moins deux arn non viraux encapsides. |
| US11124775B2 (en) | 2015-05-15 | 2021-09-21 | Flash Therapeutics | Retroviral particle comprising at least two encapsidated nonviral RNAs |
| US20190002838A1 (en) * | 2015-06-19 | 2019-01-03 | Seracare Life Sciences, Inc. | Sindbis control virus |
| EP3341018B1 (en) * | 2015-08-28 | 2026-05-20 | Wisconsin Alumni Res Found | GENERATION OF INFECTIOUS INFLUENZA VIRUSES FROM VIRUS-LIKE PARTICLES |
| CA3004132A1 (en) * | 2015-11-09 | 2017-05-18 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids |
| CN109477074B (zh) | 2016-02-19 | 2023-01-24 | 威斯康星旧生研究基金会 | 用于疫苗开发的改进的乙型流感病毒复制 |
| WO2018129268A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
| BR112019019813A2 (pt) | 2017-03-30 | 2020-04-22 | The University Of Queensland | moléculas quiméricas e usos das mesmas |
| EP3687561A4 (en) | 2017-09-01 | 2021-06-09 | The Australian National University | "immunoregulatory molecules and uses therefor" |
| MX2020003838A (es) | 2017-10-13 | 2020-08-06 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral. |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
| KR20200139679A (ko) | 2018-02-26 | 2020-12-14 | 안톨알엑스, 인크. | 면역관용성 리포솜 및 그의 사용 방법 |
| US12084698B2 (en) | 2018-07-13 | 2024-09-10 | Kyoto University | Virus-like particles and use thereof |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| EP3840780A1 (en) | 2018-08-20 | 2021-06-30 | Wisconsin Alumni Research Foundation | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| BR112021021566A2 (pt) | 2019-04-28 | 2022-04-19 | Selecta Biosciences Inc | Métodos para tratamento de indivíduos com imunidade preexistente a vetores de transferência viral |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| BR112021023594A2 (pt) | 2019-05-28 | 2022-02-08 | Selecta Biosciences Inc | Métodos e composições para resposta imune de vetor de transferência antiviral atenuada |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| US20220396806A1 (en) | 2019-07-26 | 2022-12-15 | Akouos, Inc. | Methods of treating hearing loss using a secreted target protein |
| JP7627911B2 (ja) | 2019-08-27 | 2025-02-07 | ウィスコンシン アルムニ リサーチ ファンデイション | 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス |
| EP4093415A1 (en) | 2020-01-24 | 2022-11-30 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized na |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| EP4165194A2 (en) | 2020-05-13 | 2023-04-19 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
| AR122078A1 (es) | 2020-05-13 | 2022-08-10 | Akouos Inc | Composiciones y métodos para tratar la pérdida auditiva asociada a slc26a4 |
| CN116670154A (zh) | 2020-07-24 | 2023-08-29 | 总医院公司 | 增强的病毒样颗粒及使用其递送至细胞的方法 |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| KR20230127263A (ko) | 2020-12-29 | 2023-08-31 | 아카우오스, 인크. | Clrn1-연관된 청력손실 및/또는 시력손실을 치료하기위한 조성물 및 방법 |
| US20240269265A1 (en) | 2021-06-09 | 2024-08-15 | Chimeron Bio Corporation | Peptide VLP-Based Vaccines |
| WO2022261355A1 (en) | 2021-06-09 | 2022-12-15 | Chimeron Bio Corporation | Self-amplifying rna-based vlp vaccines |
| AU2022356427A1 (en) | 2021-09-30 | 2024-05-09 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| EP4473011A1 (en) | 2022-02-02 | 2024-12-11 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| TW202408545A (zh) | 2022-07-08 | 2024-03-01 | 美國貝勒醫學院 | 整合的壓力反應抑制劑及其使用方法 |
| AU2024266138A1 (en) | 2023-05-03 | 2025-11-13 | Manifold Biotechnologies, Inc. | Methods and compositions for high-throughput protein delivery, screening, and detection |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1004083A (en) | 1911-01-09 | 1911-09-26 | Henry Ritter | Method of making sash-bars and die for forming same. |
| US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
| WO1992011291A1 (en) | 1990-12-20 | 1992-07-09 | Smithkline Beecham Biologicals (S.A.) | Vaccines based on hepatitis b surface antigen |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| WO1996030523A2 (en) | 1995-03-31 | 1996-10-03 | Hans Wolf | Antigen presentation system based on retrovirus-like particles |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
| US6099847A (en) | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
| US6555342B1 (en) | 1998-06-03 | 2003-04-29 | Uab Research Foundation | Fusion protein delivery system and uses thereof |
| US6902886B1 (en) | 1998-11-06 | 2005-06-07 | The Research Foundation Of State University Of New York | Genetic assay for protein nuclear transport |
| US20020052040A1 (en) | 1999-06-30 | 2002-05-02 | Nicholas Hunt | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
| US20020177551A1 (en) | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| US7045335B2 (en) | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
| EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
| US20080115199A1 (en) * | 2001-12-06 | 2008-05-15 | Albert Young | Scheme for device and user authentication with key distribution in a wireless network |
| US8574590B2 (en) | 2003-07-30 | 2013-11-05 | Integral Molecular, Inc. | Lipoparticles comprising proteins, methods of making, and using the same |
| FR2862982B1 (fr) * | 2003-12-02 | 2006-04-28 | Genethon | Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale. |
| US9592277B2 (en) | 2004-04-14 | 2017-03-14 | Avirid, Inc. | Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases |
| GB0426641D0 (en) | 2004-12-03 | 2005-01-05 | Bioactive Protein Delivery The | Protein delivery system |
| US9101578B2 (en) | 2006-05-01 | 2015-08-11 | Technovax, Inc. | Polyvalent influenza virus-like particle (VLP) compositions |
| DE202006010918U1 (de) * | 2006-07-14 | 2006-10-05 | Flexi-Bogdahn Technik Gmbh & Co. Kg | Leineneinrichtung für eine mechanisch auf- und abrollbare Leine zum Führen von Tieren |
| US20120121650A1 (en) * | 2006-08-18 | 2012-05-17 | Johnston Robert E | Chimeric Virus Vaccines |
| WO2009120883A2 (en) * | 2008-03-26 | 2009-10-01 | Life Technologies Corporation | Virus-like particle mediated cellular delivery |
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| EP2496609A4 (en) * | 2009-11-03 | 2013-05-08 | Ligocyte Pharmaceuticals Inc | CHIMERIC RSV-F POLYPEPTIDE AND VLPS ON LENTIVIREN OR ALPHA RETROVIRUS GAG BASE |
| EP3663395B1 (en) | 2012-03-26 | 2024-07-31 | The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology, Transfer, | Delivery of packaged rna to mammalian cells |
| KR102467982B1 (ko) | 2013-12-16 | 2022-11-16 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법 |
-
2013
- 2013-03-15 EP EP19207297.3A patent/EP3663395B1/en active Active
- 2013-03-15 EP EP13712661.1A patent/EP2831225A1/en not_active Withdrawn
- 2013-03-15 WO PCT/US2013/031876 patent/WO2013148302A1/en not_active Ceased
- 2013-03-15 US US14/388,441 patent/US9506041B2/en active Active
- 2013-03-15 AU AU2013240248A patent/AU2013240248B2/en active Active
- 2013-03-15 JP JP2015503322A patent/JP2015527296A/ja active Pending
-
2016
- 2016-06-23 US US15/190,992 patent/US10538743B2/en active Active
-
2018
- 2018-06-12 JP JP2018111489A patent/JP6585237B2/ja active Active
-
2019
- 2019-03-19 AU AU2019201911A patent/AU2019201911A1/en not_active Abandoned
- 2019-12-10 US US16/709,147 patent/US20200102545A1/en not_active Abandoned
-
2021
- 2021-10-01 AU AU2021240286A patent/AU2021240286B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018186815A5 (enExample) | ||
| Pietilä et al. | Alphavirus polymerase and RNA replication | |
| EP3663395B1 (en) | Delivery of packaged rna to mammalian cells | |
| Lundstrom | Replicon RNA viral vectors as vaccines | |
| JP2023134488A5 (enExample) | ||
| Lundstrom | Self-replicating RNA viruses for RNA therapeutics | |
| JP4790984B2 (ja) | アルファウイルスレプリコンベクター系 | |
| JP2019530466A5 (enExample) | ||
| Kim et al. | Venezuelan equine encephalitis virus nsP2 protein regulates packaging of the viral genome into infectious virions | |
| Anraku et al. | Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity | |
| Albarino et al. | Efficient reverse genetics generation of infectious Junin viruses differing in glycoprotein processing | |
| JP2010530245A5 (enExample) | ||
| Atasheva et al. | Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation | |
| Kamrud et al. | Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle | |
| WO2008119827A1 (en) | Transreplicase constructs | |
| Kowolik et al. | Preferential transduction of human hepatocytes with lentiviral vectors pseudotyped by Sendai virus F protein | |
| Polo et al. | Alphavirus DNA and particle replicons for vaccines and gene therapy. | |
| JP2019509750A5 (enExample) | ||
| Kim et al. | Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype | |
| Lundstrom | Semliki Forest virus vectors for gene therapy | |
| Hewson | RNA viruses: emerging vectors for vaccination and gene therapy | |
| EP2331557B1 (en) | Alphavirus packaging cell lines | |
| Yamanaka | Alphavirus vectors for cancer gene therapy | |
| Lundstrom | Self-replicating RNA viral vectors in vaccine development and gene therapy | |
| JP2007512827A (ja) | αウイルス由来ベクターを含むウイルス粒子、ならびに前記ウイルス粒子の調製方法 |